A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Phase 2/3Recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 490 (estimated)
- Start date
- 10 Dec 2025
- Primary completion
- Sep 2030 (estimated)
- Study completion
- 1 Sep 2030
- Last update posted
- 5 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- None
- Arms
- 6
Interventions
- Telisotuzumab Adizutecan Drug
- Standard of Care Drug
- Osimertinib Drug
Conditions and primary outcome
- Non-Small Cell Lung Cancer
- c-MET
Primary outcome
Phase 2: Objective Response (OR) Assessed by the Blinded Independent Central Review (BICR) (Up to Approximately 69 Months); Phase 3: Progression-Free Survival (PFS) as assessed by the BICR (Up to Approximately 69 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07155187.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07155187 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.